Search clinical trials for: MK-1029

Total 2369 results

Taiho Oncology, Inc.

Completed

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Advanced Solid Tumors (Excluding Breast Cancer)

United States
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

Treatment Resistant Depression

United States
Peloton Therapeutics, Inc.

Active, not recruiting

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Kidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, Recurrent

United States
Merck Sharp & Dohme LLC

Completed

MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)

Kidney Failure, Chronic | End-Stage Renal Disease

United States, Israel, Romania
Merck Sharp & Dohme LLC

Completed

A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)

Human Immunodeficiency Virus | AIDS Virus

Romania
Merck Sharp & Dohme LLC

Completed

Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)

HIV-1 Infection

Germany
Merck Sharp & Dohme LLC

Completed

Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)

HIV-1 Infection

Germany, United Kingdom
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Terminated

Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer

Rectal Cancer | Colon Cancer

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)

Renal Cell Carcinoma

China
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention Deficit/Hyperactivity Disorder

United States
Stuart Mazzone
Melbourne Health; Merck Sharp & Dohme LLC; Monash University

Recruiting

Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough

Chronic Cough

Australia
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017) CORALreef HeFH

Hypercholesterolemia | Familial Hypercholesterolemia

United States, Australia, Brazil, Canada, Chile, Colombia, Czechia, Finland, Hong Kong, Hungary, Israel, Netherlands, New Zealand, Norway, Singapore, Spain, Taiwan
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy (RECIR)

Prostate Cancer | Neuromuscular Blockade

Italy
Merck Sharp & Dohme LLC

Completed

Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)

Parkinson's Disease
Merck Sharp & Dohme LLC

Terminated

Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)

Major Depressive Disorder, Recurrent
University of Pittsburgh
Merck Sharp & Dohme LLC

Completed

Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study

Schizophrenia

United States
Agomab Spain S.L.

Recruiting

STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

Fibrostenotic Crohn's Disease

United States, Italy, Poland, Spain, Denmark, Austria, Canada, Germany
Sun Yat-sen University

Recruiting

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Pancreatic Neoplasms

China
National University Hospital, Singapore

Recruiting

A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma

Singapore
InQpharm Group

Completed

Efficacy and Safety of IQP-AK-102 in Reducing Appetite

Appetite Regulation | Energy Intake | Appetite Suppression

Germany
Xigen SA

Completed

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

Pain | Inflammation | Cataract

United States
Taiho Oncology, Inc.

Completed

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Advanced Solid Tumors (Excluding Breast Cancer)

United States
Neothetics, Inc

Completed

Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)

Thyroid-Related Eye Disease

Australia, New Zealand
RXi Pharmaceuticals, Corp.

Completed

Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109

Cicatrix | Scar Prevention
Merck Sharp & Dohme LLC

Completed

A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)

Rheumatoid Arthritis
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

Advanced or Metastatic Solid Tumors

United States, Canada, Israel, Netherlands
Merck Sharp & Dohme LLC

Completed

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Lymphoma | Solid Tumors

United States, Korea, Republic of, France, Israel, United Kingdom
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)

Hepatitis C, Chronic
Dartmouth-Hitchcock Medical Center
Dartmouth College

Completed

A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery

Head and Neck Cancer

United States
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Carcinoma, Hepatocellular | Colorectal Neoplasms | Esophageal Neoplasms | Endometrial Neoplasms | Pancreatic Ductal Adenocarcinoma | Biliary Tract Neoplasms

Israel, United States, Australia, Belgium, Chile, France, Korea, Republic of, Netherlands, Spain, New Zealand
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Melanoma

United States, Australia, France, Israel, Italy, Switzerland
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Ukraine
Merck Sharp & Dohme LLC

Completed

MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)

Human Immunodeficiency Virus

Romania, South Africa
Merck Sharp & Dohme LLC

Completed

MK-0616 (Oral PCSK9 Inhibitor) Renal Impairment Study 2 (MK-0616-020)

Hypercholesterolaemia

United States
Merck Sharp & Dohme LLC

Withdrawn

MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)

HIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)

HIV-1 Infection

Germany, Romania
West China Hospital

Recruiting

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Non-small Cell Lung Cancer

China
Merck Sharp & Dohme LLC

Completed

Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

Advanced Solid Tumors

United States, Australia, Canada, Chile, China, France, Greece, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, South Africa, Spain, Sweden
Merck Sharp & Dohme LLC

Completed

A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)

Advanced Cancer
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)

Hepatitis C
InQpharm Group

Completed

Safety and Efficacy of IQP- AK-102 in Reducing Body Weight

Weight Loss

Germany
InQpharm Group

Completed

Safety and Efficacy of IQP-AK-102 in Reducing Appetite

Weight Loss | Appetite Modulation (Focus of Study)

Germany
Tonix Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions (AtEase)

PTSD

United States
Chiesi Farmaceutici S.p.A.

Active, not recruiting

Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

Fabry Disease

United States, Netherlands, Australia, Hungary, United Kingdom, Canada, Czechia, Finland, France, Italy, Norway, Slovenia, Spain
University Medical Center Goettingen

Withdrawn

Effects of Vagus Nerve Stimulation (VNS) as a Treatment of Persistent Depression With Comorbid Personality Disorders (Impulse-VNS (Impuls-V)

Depression | Comorbid Personality Disorders

Germany
InQpharm Group

Completed

Efficacy and Safety of IQP-VV-102 in Weight Management

Obesity | Overweight

Germany
Aldeyra Therapeutics, Inc.

Completed

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

Sjogren-Larsson Syndrome

United States
Synchroneuron Inc.

Withdrawn

Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder (PTSD)

Posttraumatic Stress Disorders | Stress Disorders, Post-Traumatic | Post-Traumatic Stress Disorders | Post-Traumatic Stress Disorders, Combat-related
CinDome Pharma, Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Diabetic Gastroparesis

United States

3

Subscribe